Lysoveta

Lysoveta is a novel nutraceutical and investigational pharmaceutical product consisting of omega-3 fatty acids—eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—specifically bound to lysophosphatidylcholine (LPC)[1][2][5]. This omega-3 LPC formulation is designed to enhance targeted delivery of EPA and DHA across the blood-brain barrier and blood-retina barrier, leveraging the MFSD2A transporter, which uniquely recognizes these essential fatty acids only in the LPC-bound form[5]. Preclinical and emerging clinical studies indicate the potential of Lysoveta to support brain and eye health—most notably for cognitive function, memory, and mood in aging adults. Clinical and preclinical research also suggests potential for treating or preventing conditions such as Alzheimer’s disease, male infertility, and gestational diabetes[1][2]. Lysoveta has achieved New Dietary Ingredient (NDI) status in the United States for adult use and is currently under clinical evaluation for further regulatory approval as both a dietary supplement and a pharmaceutical therapy[5].

Brand names

Lysoveta

Other names

LysovetaLPC-EPA/DHAlysophosphatidylcholine-bound EPA/DHALPC-omega-3LPC-omega3LPC-omega 3